Sequence Based, Ai-Driven Drug Discovery Company, Deargen Raises Us$17 Million In Seriesb Financing Round To Accelerate In-House Pipeline
Amount Raised
$17 Million
Round Type
Series B
SeoulDescription
Deargen Inc., an AI-powered drug discovery and development company, announced on the 24th that it has raised US$17million in a series B financing round. This will be used to accelerate in-house pipeline by establishing a drug development research institute.
Who to call at Deargen, and when
A new round usually means Deargen is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Deargen raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Deargen, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Deargen. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Deargen raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansDeargen raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.